Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Investor Presentation (September 2011)

29 slides from Questcor Pharmaceuticals's investor presentation, Sep 12, 2011

  1. Slide 1: Questcor Investor Presentation, September 9, 2011

    NASDAQ: QCOR September 9, 2011 Exhibit 99.1 NASDAQ: QCOR September 9, 2011

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Note: Except for the historical information contained herein, this presentation contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performan

  3. Slide 3: Questcor: A biopharmaceutical company for serious, difficult-to-treat conditions

    3 Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions

  4. Slide 4: Questcor Overview

    4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $170M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • De

  5. Slide 5: History of Acthar

    History of Acthar 5 1952 First Approved 1978 MS Indication Added 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy

  6. Slide 6: Significant Barriers to Entry

    6 Significant Barriers to Entry 6

  7. Slide 7: QCOR Strategy – Sell More Acthar

    7 QCOR Strategy – Sell More Acthar Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Lupus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Erythematosus

  8. Slide 8: Acthar and MS

    8 Acthar and MS *Based on prescriptions written Problematic Steroid Side Effects Poor Venous Access Inadequate Response to Steroids Acthar when “Steroids are not suitable” Neurodegenerative disorder Acute treatment for relapses Treatment for 1-2 weeks* $40K-$50K/Rx Problematic Steroid Side Effects P

  9. Slide 9: MS Sales - Record of Consistent Growth

    9 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i

  10. Slide 10: Monthly MS Sales Are Promotion Sensitive

    10 Monthly MS Sales Are Promotion Sensitive 15-30 reps MS Paid/Shipped RX's 30-38 reps 38-77 reps

  11. Slide 11: MS Trends

    11 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q2-2011 results – Q2-11 new, paid Rxs up 147% vs. Q2-10 – MS about 60% of QCOR net sales* • Estimated $110M annualized run-rate* – About 400 prescribers in Q2 – June was a record month • Q3 new, paid Rxs run-rate up about 10% from Q2** – Augus

  12. Slide 12: Acthar and Nephrotic Syndrome (NS)

    • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6 months* • $150K-250K/Rx Acthar and Nephrotic Syndrome (NS) *Based o

  13. Slide 13: NS Sales – Off to a Good Start

    13 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the f

  14. Slide 14: Estimated total: 20,000-25,000 patients

    Estimated total: 20,000-25,000 patients _( QUESTCOR’

  15. Slide 15: NS Sales

    15 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Q1 2011 new, paid NS Rxs: 18 • 14 different prescribers – Q2 2011 new, paid NS Rxs: 45 • 37 different prescribers • 6 month course of therapy creates future vial demand • Expanding NS selling effort: 5

  16. Slide 16: NS Phase IV Company Sponsored Study

    16 • Treatment Resistant Idiopathic Membranous Nephropathy • Dose response trial – Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo – n=84 (approximate), 35 centers (approximate) – Endpoint is reduction of proteinuria • Trial milestones – First patient do

  17. Slide 17: Infantile Spasms

    17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by

  18. Slide 18: Acthar and IS

    18 • FDA approval 10/15/10 • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx – About half of patients receive drug for fre

  19. Slide 19: IS Sales

    19 • Targeting select institutions – Promotion effort being narrowed as market is maturing – Creates selling time for Acthar MS reps to target NS • Significant variability in quarterly Rxs • Q2-2011 new, paid Rxs within historic range – Acthar currently used to treat 40-50% of IS patients – Q3 new,

  20. Slide 20: Immediate Acthar Growth Opportunities

    20 Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates MS NS IS Build on sales momentum, good market headroom Market size- $500M+* Good start with 5 reps Significantly expanding selling effort Market size- $1B+* Targeted sales

  21. Slide 21: Total Acthar Sales Force

    21 • Specialty Sales Force – Main focus on MS (time split is ~ 80%/15%/5% on MS/NS/IS) – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on Nephrotic Syndrome – 28 representatives, 4 regional managers, one national director – All hired and on-boa

  22. Slide 22: Systemic Lupus Erythematosus (Lupus)

    22 • High unmet need • Serious health risk if unsuccessfully treated • Difficult to treat • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) High unmet need Serious health risk if unsucces

  23. Slide 23: Financials: Profitable, Debt Free, Cash Flow Positive

    23 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive

  24. Slide 24: Q2-2011 Financial Results

    24 Q2-2011 Financial Results Record Sales (up 62%) and Solid Earnings (EPS up 50%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 46.0 94% $20.4 $0.21 $28.3 93% $14.3 $0.14 Q2-2011 Q2-2010 Record Sales (up 62%) and Solid Earnings (EPS up 50%) Second quarter vials shipped

  25. Slide 25: Questcor is Cash Flow Positive

    25 Questcor is Cash Flow Positive Cash / ST Investments Accounts Receivable $170M* $19M 9/6/11 Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $170M* $19M 9/6/11 Debt-free balance sheet

  26. Slide 26: Share Repurchases

    26 Share Repurchases: 15 Million Shares • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 62.3 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchases significantly improve EPS 2.

  27. Slide 27: Go Forward Plan - Sell More Acthar

    27 • Sustain effort and momentum with MS • Expand NS selling effort • Maintain and gradually grow IS sales • Explore Systemic Lupus Erythematosus (Lupus) as next vertical market • Develop other markets for Acthar • No business development efforts planned Go Forward Plan - Sell More Acthar Sustain ef

  28. Slide 28: Acthar has sustainable competitive advantages

    Acthar has sustainable competitive advantages- without FDA approval risk ‘Acthar is approved for 19 indications-many in large markets with sizable unmet need Salesin MS and NS are growing rapidly, yet market penetration is low Announced new vertical market— Lupus High margins provide good operating

  29. Slide 29: September 9, 2011

    NASDAQ: QCOR September 9, 2011 NASDAQ: QCOR September 9, 2011

Questcor Pharmaceuticals — Investor Presentation (September 2011) on 6ix